Cited by 770Immune cells in cancerCancer Immunotherapy and BiomarkersChemokine receptors and signaling

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Open access

Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L.·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3007974PMC PMC6980372

Open this paper in CoChat — free account

Abstract

Preventing trafficking of myeloid-derived suppressor cells to the tumor site enhances the efficiency of checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007974

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Signaling of PD1 on T cells via PD-L1 (B7-H1) or PD-L2 (B7-DC) inhibits T cell receptor–mediated activation by recruitment of the SHP2 phosphatase (2).”
Background
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Combination regimens appear to be even more potent with response rates of 53% in metastatic melanoma (22).”
Background
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“These results are consistent with previous reports demonstrating that GrMDSCs at the tumor site are highly dependent on migration from the BM or spleen and undergo minimal proliferation within the tumor bed (13).”
BackgroundResult
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261

Show all 50 references

Sorted by citations

Items 701–770 of 770

Strategies to overcome interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer
Puthenveetil, A., Dubey, S., & Garg, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824273-5.00004-0
Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · doi:10.1158/1078-0432.24710470
Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · doi:10.1158/1078-0432.24710470.v1
Myeloid-Derived Suppressive Cells in the Tumor Contexture
Derré, L. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_381-1
Cytokines and Chemokines in the Nervous System in Health and Disease
Azizi, G., & Rostami, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00248-7
Trial protocol 1 from Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch-repair deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2024) · doi:10.1158/1078-0432.27031387.v1
Boiling Histotripsy Combined with Anti-SIRPα Ab Enhances Immunomodulation in YUMM1.7 MelanomaPreprint
Chandrasekar, S. V., Singh, A., Chamani, F., & Ranjan, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4993692/v1
Janus-faced role of neutrophils in cancer
Mayadas, T. N., & Luo, H. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90001-8
Designing a CXCL8-hsa chimera as potential immunmodulator of the tumor micro-environment
Gerlza, T., Trojacher, C., Fuchs, T., Atlić, A., Weís, R., Adage, T., & Kungl, A. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1539733
“Inhibiting MDSC traf ﬁ cking to the tumor enhances the potency of PD-1 (programmed cell death protein 1) checkpoint blockade (49, 50).”
Checkpoint Blockade in Hematologic Malignancies
Charalambous, A., & Schwarzbich, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_178
Myeloid-Derived Suppressive Cells in the Tumor Contexture
Derré, L. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_381
Regulation of tumor progression by myeloid cells
Jaya, F. N. M., & Gabrilovich, D. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00038-2
Additional file 1 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370974
Additional file 4 of Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590802
Additional file 2 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370977
Additional file 3 of Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590799
Additional file 1 of Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Tenorio-Pedraza, J. M., Lippert, J., Burghaus, R., & Scheerans, C. (2023) · Figshare · doi:10.6084/m9.figshare.23961998
Additional file 1 of Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway
Zhang, Y., Lei, Y., Ou, Q., Chen, M., Tian, S., Tang, J., Li, R., Liang, Q., Chen, Z., & Wang, C. (2024) · Figshare · doi:10.6084/m9.figshare.25656064
Additional file 4 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370983
Additional file 5 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370986
Additional file 2 of Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590796
Additional file 1 of Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma
Wang, H.-Y., Yang, F.-C., Yang, C.-F., Liu, Y.-C., Ko, P.-S., Li, C.-J., Tsai, C.-K., Chung, Y.-L., & Chen, N.-J. (2023) · Figshare · doi:10.6084/m9.figshare.22618984
Additional file 6 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370989
Additional file 3 of Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370980
Additional file 1 of Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590793
Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors
Patel, M., der Jeught, K. V., & Datta, J. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.004
CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors
Wang, X., Xue, S., Li, Y., Yang, M., Yu, H., Wang, M., Li, S., Lu, Z., & Luo, M. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013336
“…inhibitors reduce tumor growth by blocking PMN-MDSC tumor infiltration and synergize with anti-programmed cell death protein 1 (PD-1) antibodies, 28 inhibition of FATP2 abrogates PMN-MDSC suppressive functions and sensitizes tumors to anti-CTLA4 (cytotoxic T lymphocyte-associated antigen-4)…”
IL-1α drives a tumor-stroma-neutrophil axis through inflammatory fibroblast activation in head and neck cancerPreprint
Hanschmann, E.-M., Bruderek, K., Hofmann-Vega, F., Schmidt, M., Budeus, B., Oberlies, W., Wei, X., Richter, M., Lemm, S., Szlachetko, J. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700440
Caerin 1.1/1.9 peptides cooperate with 5-fluorouracil to suppress melanoma by reprogramming myeloid suppressor cells and regulatory T cellsPreprint
Song, X., Fu, J., Fu, Q., Li, J., Luo, Y., Li, H., Liu, X., Ni, G., & Wang, T. (2026) · Research Square · doi:10.21203/rs.3.rs-8780310/v1
Tumor-intrinsic ETV5 expression promotes PMN-MDSC-mediated immune evasion and immune checkpoint inhibitor resistance by activating the JAK2/STAT3/CCL2 axis
Yin, T.-T., Huang, M.-X., Liu, M.-C., Luo, P., Da, T.-T., Huang, C., Yang, P., Yao, Y., & Cao, J. (2026) · Oncogene · doi:10.1038/s41388-026-03686-z
Association between splenic volume changes and prognosis in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy
Li, Z., Liu, W., Zhang, G., Fu, X., Li, Y., Lou, J., Gong, B., Li, L., Yang, L., & Zhang, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1763993
Cx 2 Mab-5: A Novel Anti-Mouse CXCR2 Monoclonal Antibody Developed by N-Terminus Peptide Immunization for Multiple Applications
Taruta, H., Tanaka, T., Kaneko, M. K., Suzuki, H., & Kato, Y. (2026) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1177/21679436251415261
Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy
He, Y., & Yeo, Y. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70052
“An antibody blocking CXCR2 significantly reduced the number of circulating and intratumoral MDSCs, thereby enhancing the efficacy of anti- PD-1 therapy in a preclinical rhabdomyosarcoma model (Highfill et al. 2014).”
Mitochondria and resistance to immunotherapy
Adhikary, K., Chakraborty, A., Chatterjee, S., Ganguly, K., & Maiti, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40535-8.00008-9
Caractérisation clinique et biologique de l’hyperprogression tumorale lors du blocage de la voie PD-1/PD-L1
Champiat, S. (2019) · theses.fr (ABES) · doi:10.70675/e358773dz1898z4feezbb3bzbdee7c7f20a6
L'activité kinase de FAK dans les fibroblastes associés au cancer : régulateur clé de la progression de l'adénocarcinome pancréatique canalaire
Zaghdoudi, S. (2019) · theses.fr (ABES) · doi:10.70675/6a05c34bz13e4z4f0bzb211zd3bd71932f70
Exploiting DNA Repair Vulnerabilities to Modulate Anti-Cancer Immunity : a Study of the Immunological Potential of PARP inhibitors
Chabanon, R. M. (2019) · theses.fr (ABES) · doi:10.70675/00b851efzb998z4aaczb6baz4ab892005882
Causal relationship between GM, immune cells and esophageal adenocarcinoma: a mediation analysis based on MR
He, W., Gao, M., Ren, Q., Wang, M., Zhou, S., Liu, Q., Chu, K., Qin, Y., Fan, Y., Zou, H., et al. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03984-3
“…that proportion-based metrics may not directly index functional suppressive capacity, whereas surface molecules such as CD11b may better reflect adhesion/migration and recruitment programs that facilitate trafficking of suppressive myeloid cells to relevant tissues and promote immune escape [59].”
Self-citation
Characterization of tumor-infiltrating myeloid cells in a mouse model of melanoma : roles of IL-4Rα signaling and tumor cell immunogenicity
Baudoin, E. (2021) · theses.fr (ABES) · doi:10.70675/bf86ac7ezf6a3z4f56z82e8zacc0b861cdac
CD55-expressing myeloid-derived suppressor cells (MDSCs) drive cancer immunoevasion
Jiang, X., Yan, N., Wu, H., Wang, W., Wang, X., Chen, J., Wu, A., An, J., Wang, C., Lin, J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012980 · Cited by 1
“33 Dysregulation of CD55 has been linked to various non-malignant conditions, including autoimmune diseases such as arthritis, 55 as well as viral infections such as HIV, SARS- CoV-2, and parainfluenza virus 5.”
Dose-dependent bidirectional effects of gemcitabine in 4 T1 breast tumors are associated with angiogenesis and PMN-MDSC–linked immunosuppression
Chen, Y., Zheng, Q., Liu, H., Wu, C., & Feng, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116645
Microbiome-derived hydroxyphenyl propanoates enhance antitumour immunity by potentiating gasdermin D activity in tumour-associated myeloid cellsPreprint
Sikdar, S., Kim, D., Wang, T., Benaoudia, S., Rajwani, J., Ellestad, K. K., Douglas, P., Filandrová, R., Verhey, T. B., Ellestad, K. I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.23.720410
BRIDGE prioritizes human and mouse gene correspondences using functional and disease evidencePreprint
Yan, J., & Cao, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.10.720506
A review on in-silico analysis of immune cell trafficking and interactions with the tumour microenvironment
Kharan, P., Mathew, A. S., Ghosh, P., & Syama, H. P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1835062
“Moreover, the QSP modelling suggests that inhibiting CXCR2 or CCR2 may reduce MDSC traf ﬁ cking, thereby restoring chemokine gradients for effector cell in ﬁ ltration and enhancing the activity of checkpoint blockade therapies (146).”
Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer
Luo, M., Shen, F., Xu, W., Corpe, C. P., & Wang, J. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2699508
“99,100 The PDAC TME is a highly coordinated ecosystem in which CAFs remodel the stroma and shape immune exclusion, while lymphoid and myeloid cells exhibit profound dysfunction.”
Systemic administration of all-trans retinoic acid modulated circulating immune cells but failed to improve healing in a preclinical model of musculoskeletal trauma
Guyer, T., Gill, D., Leguineche, K., Link, K. A., Jones, K. A., Williams, K. E., Strait, L. K., O’Neill, K. L., Hastings, M. A., Lin, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1683993
NLRC3 enhances antitumor immunity by specifically negatively regulating M-MDSCs in a STING-dependent manner
Fu, Y., Zhan, X., Liu, S., Xie, Q., Song, S., Wu, S., Sheng, J., He, H., You, X., Ling, Q., et al. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01453-4
Neutrophil metabolic heterogeneity as a novel target in diseases
Zhang, Y., Guo, M., Zhao, D., Liu, H., Ding, X., Yuan, X., Jiang, Y., Feng, D., & Wang, X. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03112-7
Utilizing nanomedicines to modulate myeloid-derived suppressor cells: Enhancing cancer immunotherapy
Kumbhar, S., & Bhatia, M. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00006-1
Hypoxia drives ferroptosis resistance and immunosuppression in hepatocellular carcinoma by inducing UBASH3B-mediated glutamine metabolism reprogramming and CXCL8 expression
Pan, G., Zhang, S.-P., Wang, X., Qu, Y., Liu, X., Yan, Y., Li, T., & Dong, Z. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104342
“CXCL8 recruits myeloid-derived suppressor cells (MDSCs) and enhances endothelial cell function through CXCR2 signaling in various cancer types [54,55].”
Irradiation-based development of tumor vaccines: Mechanistic insights and translational exploration
Tian, J., Feng, X., Yu, B., Zhang, J., Jing, J., & Jin, X. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105516
B7-H3 (CD276) regulates myeloid-derived suppressor cell differentiation in pulmonary fibrosis
Santos, F. G. D. L., Rosek, A., Ando, A., Phan, S. H., Mahadevan, N. R., & Liu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1903767
“More recently, B7-H3 has been implicated in the expansion and recruitment of immature myeloid cells, including MDSCs, to tumor sites and ﬁ brotic lesion areas (7, 18, 20, 31 – 33 – 35).”
Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions
Treffert, S. M., Heneka, Y. M., Martin, J., Gargano, A., Launhardt, L., Akilli‐Öztürk, Ö., Stanganello, E., Andrieux, G., Hoch, D., Sonnentag, S. J., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09155-5
“IL-6, IL-8 and CCL2 were shown to affect the polarization of macrophages into tumor-promoting M2 TAMs [12], to drive the conversion of DCs into regulatory DCs [14] and to support MDSC differentiation and recruitment [13, 53], all suppressing a functional T cell response [38].”
From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy
Zhang, L., Zhang, K., Chen, Z., & Lu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919864
Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies
Ko, D., Park, S., Nam, K.-H., Choi, J., & Lee, K. (2026) · Immune Network · doi:10.4110/in.2026.26.e31
“The environment is also populated by suppressive cells—Tregs, myeloid-derived suppressor cells, and protumoral macrophages—that release inhibitory cytokines or directly stifle T-cell proliferation and function (36,37), helping the tumor stay hidden from the immune system.”
Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review
Bartusik‐Aebisher, D., Raj, D. R. J., Wilk, I., & Aebisher, D. (2026) · Molecules · doi:10.3390/molecules31173124
“Other strategies include the C-C chemokine receptor 2 (CCR2) and C-X-C chemokine receptor 2 (CXCR2) which can possibly obstruct the entry of suppressive monocytes and granulocytic MDSCs into the tumours [72].”
Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects
Deng, R., Bai, X., Yang, J., Ye, W., Liu, Q., Xing, Y., Yao, Y., He, X., Lü, A., & Liu, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02998-6
Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Shao, S., Diehl, M. I., & Jones, C. N. (2026) · Advanced Science · doi:10.1002/advs.77572
“…showing that CXCR1/2 inhibition to block neutrophil recruitment improves the efficacy of T cell checkpoint blockade in mice [ 99, 103, 105, 106, 108, 113 ], human cell-based organ-on-a-chip models could also be leveraged to evaluate combination immunotherapies targeting neutrophils and T cells…”
Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications
Wen, J., Zhou, Q., Yue, J., Zhang, Y., Zheng, Y., & Xu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1815669
“…of PMN-MDSCs — either through CXCR2 gene knockout or via small-molecule CXCR2 inhibitors — signi ﬁ cantly improved outcomes in metastatic sarcoma models and enhanced the ef ﬁ cacy of anti-PD-1 therapy against established tumors (155) (solid tumor evidence; relevance to MM remains to be con ﬁ rmed).”
Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation
Li, X., Meng, Y., Dong, J., Ma, Y., Liu, D., Zhang, X., & Zhao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1941235
Innate immune signaling–driven myeloid remodeling in cancer: inflammatory amplification, immune suppression, and therapeutic targeting
Ye, W., Zhong, L., Wang, X., & Chen, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1941227
COL10A1 at the crossroads of tumor signaling networks and environment remodeling
Wei, E., Guo, X., Wang, K., Gu, W., Zhang, Y., Xianli, W., & Sun, C. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156704
Nanocarrier-mediated immune microenvironment remodelling in osteosarcoma
Fu, J., Bi, Z., Wei, R., Lv, S., & Guo, Y. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103181
Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential
Lu, Y., Wang, X., Yin, C., Wang, J., Guo, S., Wang, Z., Zhou, J., Cui, M., Cheng, X., Zhang, L., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00623-0
“The CXCL1/2–CXCR2 axis further sustains immunosuppression through MDSC accumulation and impaired CD8 ⁺ T-cell function [246–249] (Fig.”
Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy
Wang, M., Chen, J., 吴中华, Wang, Z., Zhong, Z., & Zhong, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-01011-0
“Small-molecule antagonists targeting CXCR1/2 (such as SX-682 or Reparixin) can serve as receptor occupancy agents, blocking ligand-induced receptor conformational changes and internalization [34, 158].”
Tumor endothelial cells as vascular immune gatekeepers: reprogramming the vascular-immune interface for cancer immunotherapy
Zhang, T., Zhang, C., Wang, C., Sun, M., Wei, J., Yu, J., Sui, L., & Ma, W. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218908
Peripheral immune tolerance as a driver of tumor immune escape and therapy resistance
Vaishnave, S., Jayaraj, A., Selvaraj, J., Ramachandiran, S., Natarajan, M., Gunasekaran, B., & Lokaiah, T. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04590-4
CXCR2 associated neutrophil stromal interactions and immune exclusion in microsatellite stable colorectal cancer
Peng, T., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1967647
“Preclinical traf ﬁ cking studies support testing these approaches (46, 47), but a fall in circulating neutrophils does not show that a suppressive tumor population has been removed.”
BindingDB Entry 50007080: Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.
BindingDB (2021) · UC San Diego · doi:10.7270/q2057k6q
Chemokine-driven angiogenesis and inflammation in diabetic wounds: Mechanistic insights and therapeutic strategies
Liu, L., Guo, X., Dai, Y., Zhang, Q., Yang, J., Gu, R., Tang, M., Tan, M., & Nie, X. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102567

Authors: Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Mackall, Crystal L.
ORCID: Highfill, Steven L.
Cui, Yongzhi
Giles, Amber J.
Zhang, Hua
Kaplan, Rosandra N.
Mackall, Crystal L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-05-21
Volume: 6
Issue: 237
Pages: 237ra67-237ra67
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3007974
PMC: PMC6980372
OpenAlex: W2171524684
Cited by: 767
References: 50
Citations by year: 2026: 55 · 2025: 62 · 2024: 57 · 2023: 83 · 2022: 73 · 2021: 100 · 2020: 91 · 2019: 60 · 2018: 52 · 2017: 52 · 2016: 38 · 2015: 31 · 2014: 12
FWCI: 20.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01SC010289)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords: CXCR2, myeloid-derived suppressor cells, tumor immune evasion, anti-PD-1 therapy, rhabdomyosarcoma, pediatric sarcoma, interleukin-8, PD-L1, tumor immunosuppression
MeSH terms: Adolescent, Adult, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Child, Child, Preschool, Female, Humans, Male, Mice, Inbred C57BL, Prognosis, Rhabdomyosarcoma, Time Factors, Neoplastic Stem Cells, Case-Control Studies, Cytokines, Interleukin-8, Mice, Knockout, Tumor Escape, Receptors, Interleukin-8B, CD11b Antigen, Cell Line, Tumor, Tumor Burden, Mice, Chemokine CXCL1, Young Adult, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks